Oncotarget: The Journal That Helps Push The Research For Cancer Cure

There are numerous articles you can read about Oncotarget today, and most of them would not be able to tell you everything about it. In this article, we will conflate most of the pieces that you need to make sure that you can learn about what’s the latest thing about Oncotarget without wasting your time. Sure, most of what you read online is ethereal and will disappear after one reading. We will try to address that in this article. Shall we go on?

The Oncotarget Recap

One of the many articles you need to read from Oncotarget is the one about Genetic Polymorphisms in HLA-DP and its relationship with STAT4 nephropathy. In one of the most stellar research articles in ResearchGate, it is shown that Oncotarget was able to be the publishing journal who spread the information about the pathogenesis of IgA Nephropathy. In the ResearchGate article, it was shown that IgA nephropathy or (IgAN) can be initiated by what is now known as the Glomerular Deposition of Polymeric IgA1. Check Oncotarget at scimagojr.com

You can also see from the abstract of this article the information from Oncotarget that states how the new development in genetics and pathogenesis is able to find new ways to address the issues of diseases. It is also shown in the article that the local pathogens in one’s body could be related to the multilocus adaptation of the cells in one’s body.

It is also an added information from Oncotarget the statement that the perspective of the existing treatment options today in addressing kidney disease concerns should be able to find new affordable means. That should be the goal of medicine. This, fortunately, is what is driving Oncotarget to publish more journals. Watch this video on Youtube.

The EurekaAlert Article

Another interesting and relevant info you should learn, too, about Oncotarget is that it is one of the publishing firms that have found alternative therapies to thyroid cancer and other diseases. With EurekaAlert’s feature about Oncotarget’s research, it is now evident that Oncotarget is getting more relevant in its pursuit to fix all the necessary problems ingrained in the medical issues of curing thyroid cancer.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

What Clay Siegall Feels When Fighting Diseases

Seattle Genetics, one of the most important companies in the research of new therapies and treatments for diseases like cancer, has a long history since its foundation.

It was created and established in 1998 by Dr. Clay Siegall, the founder and CEO of the corporation, and the current leader and supervisor of all the researches and studies that are being conducted in his facility. His company is based in Seattle.

Having studied Zoology in the University of Maryland, but later acquiring his Ph.D. in Genetics, he has changed his interests from zoology to oncology and the study of diseases, genetics, and science in a molecular level. He acquired his Ph.D. from the renowned George Washington University.

During his first years as a research supervisor at Seattle Genetics, the entrepreneur managed to develop the first-ever FDA-approved antibody-drug conjugate, or ADC for short. The name of the drug is ADCetris, one of the most famous ADC’s in the world, being consistently used by many researchers from different countries around the globe.

Past the incredible achievement of having their ADC approved by FDA, which is the Food and Drug Administration federal administration agency, the company also developed many other drugs that are used in an international level, with more than 20 drugs under the company’s portfolio.

Dr. Clay Siegall supervised all of the researches done in his company’s labs, and most of them had the participation of Siegall in the development of their compositions as well, as he is considered an expert, or even a genius, in the field. This holds true for the antibody-drug conjugate that the team developed, as it was explicitly supervised by Siegall and had its formula retouched countless times to maximize its effectiveness and reduce any side effects to the person’s health and well-being.

As a medicine enthusiast, Clay Siegall always answers interviews with a smile on his face. Seattle Genetics, for the entrepreneur, was a dream come true, as he always felt a great sense of achievement whenever he knew he was helping humankind overcome some of the worst diseases that currently exist.

For someone who started with zoology, concluded Dr. Siegall, the field of genetics proved to be a pleasant surprise.